New Rhein

Butterfly Medical is a medical-device start-up that aims to improve the standard of care for men suffering from Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has developed a fast, simple and minimally invasive alternative treatment to first-line BPH medication and surgery. Butterfly Medical’s patented device can be placed in under 10 minutes, in-office, under local anesthesia, without surgical incision, heating or prostate tissue removal. The device aims to be the only in-office BPH treatment that delivers a long-term, effective solution with minimal side effects, requiring no hospitalization or general anesthesia. Early results from clinical trials are very promising with blocked urethras successfully opened and patients suffering no side effects. Further clinical studies are starting in leading medical centers in Europe. Visit www.butterfly-medical.com for more information.

American Injectables is a sterile injectable manufacturer of parenteral drugs with a world-class facility focused on ready-to-use pre-filled syringes and vials.

Neuraptive Therapeutics is a medical technology company that brings novel products to patients with peripheral nerve injuries. Neuraptive was founded to commercialize innovative technology from the University of Texas. Its franchise therapeutics product is designed for administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves. Founded in 2016, Neuraptive Therapeutics is headquartered in Lafayette, Colorado.

Neuraptive Therapeutics is a medical technology company that brings novel products to patients with peripheral nerve injuries. Neuraptive was founded to commercialize innovative technology from the University of Texas. Its franchise therapeutics product is designed for administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves. Founded in 2016, Neuraptive Therapeutics is headquartered in Lafayette, Colorado.

Softhale is a medical device company focused on the development of Soft Mist Inhalation (SMI) devices for the delivery of pharmaceutical drugs to the lungs.

Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with neuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval. Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high. Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD.

Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.